The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
January 27th 2023
Multiple adalimumab biosimilars will hit the US market in 2023, but the drug is still projected to have the largest price increase for the calendar year starting July 1.
US Biosimilars Substantially More Expensive Than Those in Germany, Switzerland
December 5th 2022Due to anticompetitive practices, the United States lags Germany and Switzerland in the number of biosimilars on the market, while also having substantially higher prices for both biosimilars and reference products.
Read More
Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts
November 26th 2022Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Read More
The Price Paradox of Biosimilar-Like Long-Acting Insulin
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.
Read More
Rheumatologists Grow More Comfortable With Biosimilars, but Concerns Remain
November 4th 2022Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Read More
Medicare Part B Pricing Changes Aimed at Encouraging Biosimilar Use Begin
October 3rd 2022One of the first parts of the landmark Inflation Reduction Act took effect Monday; it boosts the add-on payment for qualifying biosimilars whose average sales price is not more than the price of its reference product from 6% of the reference product’s ASP to 8% for 5 years.
Read More
Multiple Pegfilgrastim Administration Options Allow for Patient-Centric Model of Care
September 20th 2022With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.
Read More
Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer
September 14th 2022The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy) and metastatic (palliative therapy) breast cancer using real-world data.
Read More
Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan Wilfong
September 11th 2022While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.
Read More
The Biosimilar Conversion Journey Went Through 2 Phases at Minnesota Oncology
September 4th 2022While initially there was a need for education around biosimilars, now there is a need to keep an eye on the evolving biosimilar marketplace and update the formulary of biosimilar medicines, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Read More
Gap After OCM May Cause Some Practices to Switch From Biosimilars to Brand Drugs
September 1st 2022The 1-year gap after the end of the Oncology Care Model (OCM) means some practices have to make hard decisions regarding cost of care or the financial health of the practice, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.
Read More
Data Support Safety, Effectiveness of Biosimilar-to-Biosimilar Switching
August 3rd 2022Although there is a paucity of data of switching among biosimilars of the same reference product, the few studies published support the safety and effectiveness of transitioning patients from one biosimilar to another.
Read More